Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Electron microscopy images of brain autopsy case II-2

Published byEdwin Atkinson Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Electron microscopy images of brain autopsy case II-2"— Presentation transcript:

1 Figure 3 Electron microscopy images of brain autopsy case II-2
Electron microscopy images of brain autopsy case II-2 (A) Frontal cortex. Intraneuronal storage of lipofuscin-like inclusions. Magnification: ×5,750. (B) Occipital cortex. Neuronal inclusion showing a granular pattern and densely packed short lamellar profiles, coarser granular compounds, and lipid droplets. Magnification: ×41,000. (C) Nucleus dorsomedialis of the thalamus. Intraneuronal intermingled granular and lamellar complexes. Magnification: ×27,000. (D) Temporal cortex. Predominance of fingerprints in a neuronal inclusion. Magnification: ×52,500. (E) Brain biopsy of a 34-year-old female patient without neuronal ceroid lipofuscinosis (control). Intraneuronal classical lipofuscin. Magnification: ×41,000. (F) Electron microscopic examination of skin biopsy case II-5. Lipofuscin-like inclusion with an uncommon heterogeneous pattern in an endothelial cell of a blood vessel. Magnification: ×27,000. Scale = 1 μm. Julie van der Zee et al. Neurol Genet 2016;2:e102 © 2016 American Academy of Neurology

Download ppt "Figure 3 Electron microscopy images of brain autopsy case II-2"

Similar presentations

47-year-old with progressive upper limb weakness Teaching NeuroImages Neurology Resident and Fellow Section © 2014 American Academy of Neurology.

47-year-old with progressive upper limb weakness Teaching NeuroImages Neurology Resident and Fellow Section © 2014 American Academy of Neurology.
Paul M. George, Gary K. Steinberg  Neuron 

Paul M. George, Gary K. Steinberg  Neuron 
Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.

Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.
Figure 1 Imaging, histopathology, and molecular evaluation of case 1 with definite leptomeningeal angiomatosis Imaging, histopathology, and molecular evaluation.

Figure 1 Imaging, histopathology, and molecular evaluation of case 1 with definite leptomeningeal angiomatosis Imaging, histopathology, and molecular evaluation.
Figure 2 Needle biopsy of the left vastus lateralis

Figure 2 Needle biopsy of the left vastus lateralis
Figure 1 Immunofluorescence pattern of patient septin-5-immunoglobulin G binding to mouse tissues Immunofluorescence pattern of patient septin-5-immunoglobulin.

Figure 1 Immunofluorescence pattern of patient septin-5-immunoglobulin G binding to mouse tissues Immunofluorescence pattern of patient septin-5-immunoglobulin.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Sural nerve electron microscopy

Figure Sural nerve electron microscopy
Figure 2 Muscle pathology of patients 2, 26, 11, 9, 32, and 48

Figure 2 Muscle pathology of patients 2, 26, 11, 9, 32, and 48
Electron Microscopy at Scale

Electron Microscopy at Scale
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.

Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.
Figure 1 MRI, pathology, and EEG findings(A) Axial fluid-attenuated inversion recovery (FLAIR) MRI sequences of the brain showing right frontal and parietal.

Figure 1 MRI, pathology, and EEG findings(A) Axial fluid-attenuated inversion recovery (FLAIR) MRI sequences of the brain showing right frontal and parietal.
Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.

Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.
Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏

Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏
Figure 1 Neuropathologic examination of brain areas with normal MRI appearance and with gadolinium enhancement (patient 1)‏ Neuropathologic examination.

Figure 1 Neuropathologic examination of brain areas with normal MRI appearance and with gadolinium enhancement (patient 1)‏ Neuropathologic examination.
Volume 50, Issue 1, Pages (January 2014)

Volume 50, Issue 1, Pages (January 2014)
Figure MRIs and histopathology of the biopsy specimens

Figure MRIs and histopathology of the biopsy specimens

Similar presentations

Ads by Google